Haleon (LON:HLN) Insider Blathnaid Bergin Purchases 7,670 Shares of Company Stock

Haleon plc (LON:HLN) insider Blathnaid Bergin acquired 7,670 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were bought at an average cost of GBX 324 per share, for a total transaction of £24,850.80.

Haleon Price Performance

Shares of Haleon stock opened at GBX 318.25 on Monday. The stock has a market capitalization of £27.99 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. Haleon plc has a 1-year low of GBX 310.50 and a 1-year high of GBX 433.60. The firm’s 50-day moving average price is GBX 352.97 and its two-hundred day moving average price is GBX 360.40.

Haleon (LON:HLN) last announced its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, equities analysts predict that Haleon plc will post 19.50 earnings per share for the current fiscal year.

Haleon announced that its Board of Directors has initiated a share buyback plan on Thursday, October 29th that permits the company to buy back £500 million in shares. This repurchase authorization permits the company to reacquire up to 1.8% of its stock through open market purchases. Share repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms have issued reports on HLN. Berenberg Bank cut their price objective on shares of Haleon from GBX 514 to GBX 365 and set a “buy” rating for the company in a report on Monday. Deutsche Bank Aktiengesellschaft raised Haleon to a “hold” rating and reduced their target price for the company from GBX 320 to GBX 310 in a report on Friday. Royal Bank Of Canada upped their price objective on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 400 target price on shares of Haleon in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of GBX 356.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.